These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19546365)

  • 21. Problems related to determination of MICs of oximino-type expanded-spectrum cephems for Proteus vulgaris.
    Ohno A; Ishii Y; Ma L; Yamaguchi K
    J Clin Microbiol; 2000 Feb; 38(2):677-81. PubMed ID: 10655366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility and distribution of extended-spectrum β-lactamases, AmpC β-lactamases and carbapenemases among Proteus, Providencia and Morganella isolated from global hospitalised patients with intra-abdominal and urinary tract infections: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2008-2011.
    Yang JH; Sheng WH; Hsueh PR;
    J Glob Antimicrob Resist; 2020 Sep; 22():398-407. PubMed ID: 32311502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro activity and beta-lactamase stability of CGP 31523A, a new aminothiazolyl cephalosporin.
    Chin NX; Neu HC
    Chemioterapia; 1986 Apr; 5(2):92-100. PubMed ID: 3518967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosomal beta-lactamase expression and resistance to beta-lactam antibiotics in Proteus vulgaris and Morganella morganii.
    Yang YJ; Livermore DM
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1385-91. PubMed ID: 3058021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of an oxycephem OCP 9-176 compared with its sulfur analog and other beta-lactams.
    Gu JW; Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1991; 14(2):135-40. PubMed ID: 1873972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
    Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
    Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital.
    Tumbarello M; Citton R; Spanu T; Sanguinetti M; Romano L; Fadda G; Cauda R
    J Antimicrob Chemother; 2004 Feb; 53(2):277-82. PubMed ID: 14688041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromosomally encoded cephalosporin-hydrolyzing beta-lactamase of Proteus vulgaris RO104 belongs to Ambler's class A.
    Péduzzi J; Reynaud A; Baron P; Barthélémy M; Labia R
    Biochim Biophys Acta; 1994 Jul; 1207(1):31-9. PubMed ID: 8043607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidrug-resistant Providencia stuartii expressing extended-spectrum beta-lactamase PER-1, originating in Kosovo.
    Poirel L; Bruderer T; Frei R; Bernabeu S; Graber P; Nordmann P
    J Antimicrob Chemother; 2008 Jun; 61(6):1392-3. PubMed ID: 18334492
    [No Abstract]   [Full Text] [Related]  

  • 33. Simultaneous production of two types of beta-lactamase in Escherichia coli and Providencia stuartii.
    Letarte R; Devaud-Felix M; Pechere JC; Roy B
    Can J Microbiol; 1978 Oct; 24(10):1153-7. PubMed ID: 365308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
    Jones RN; Salazar JC; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
    Schneider I; Queenan AM; Markovska R; Markova B; Keuleyan E; Bauernfeind A
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4518-21. PubMed ID: 19620330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nosocomial dissemination of plasmids carrying blaTEM-24, blaDHA-1, aac(6')-Ib-cr, and qnrA6 in Providencia spp. strains isolated from a Tunisian hospital.
    Mahrouki S; Chihi H; Bourouis A; Ayari K; Ferjani M; Moussa MB; Belhadj O
    Diagn Microbiol Infect Dis; 2015 Jan; 81(1):50-2. PubMed ID: 25315769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
    Neu HC; Chin NX; Jules K; Labthavikul P
    J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory investigation of a suspected outbreak caused by Providencia stuartii with intermediate resistance to imipenem at a long-term care facility.
    Mao YC; Chang CL; Huang YC; Su LH; Lee CT
    J Microbiol Immunol Infect; 2018 Apr; 51(2):214-219. PubMed ID: 27553450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals.
    Zemelman C; Bello H; Domínguez M; González G; Mella S; Zemelman R
    Diagn Microbiol Infect Dis; 2001; 40(1-2):41-3. PubMed ID: 11448562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.